THOMAS E. HUGHES, B.S.; JEFFREY D. ALMGREN, B.S.; ROBERT W. MCGUFFIN, M.D.; ROBERTA J. OMOTO, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Co-trimoxazole (trimethoprim sulfamethoxazole) is a safe and effective oral anti-infective agent commonly used in recipients of bone marrow transplants for prophylaxis against infection, particularly Pneumocystis carinii pneumonia. Since the institution of co-trimoxazole as a prophylactic agent, the morbidity of P. carinii interstitial pneumonia has decreased (1, 2). However, the occurrence of a hypersensitivity reaction to co-trimoxazole can prevent its administration. Penicillin V may be substituted for bacterial prophylactic coverage after transplantation, but it is not effective against P. carinii. Successful desensitization to co-trimoxazole would permit continued use of this most effective agent for prophylaxis or treatment of
HUGHES TE, ALMGREN JD, MCGUFFIN RW, et al. Co-trimoxazole Desensitization in Bone Marrow Transplantation. Ann Intern Med. 1986;105:148. doi: https://doi.org/10.7326/0003-4819-105-1-148
Download citation file:
Published: Ann Intern Med. 1986;105(1):148.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use